News Releases

- Clinical updates for both Reducer™ and Tiara™ also presented at premier event - NASDAQ, TSX: NVCN VANCOUVER, Dec. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 27, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that Chris Clark, chief financial officer, is scheduled to present at the 29th Annual Piper Jaffray ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 17, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the "Series A ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 14, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September 30, 2017 (all figures in U.S. dollars unless otherwise ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 10, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 9, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 Series A units (the "Series A Units") of Neovasc and 19,066,780 ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced that it has received approval of the U.S. Food and Drug Administration ("FDA") to initiate the COSIRA-II IDE pivotal ...

NASDAQ, TSX: NVCN VANCOUVER, Nov. 3, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) reported today that the United States Court of Appeals for the Federal Circuit affirmed the judgment of the United States District ...

NASDAQ, TSX: NVCN VANCOUVER, Sept. 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral ...

Review serves to update clinicians as to current evidence and future perspectives on the optimal utilization of this innovative technology NASDAQ, TSX: NVCN VANCOUVER, Sept. 5, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, ...